squiffy2
07-07-2008, 03:51 AM
Teva Pharmaceutical Industries Ltd. announced top-line results from a Phase III study designed to assess the efficacy, safety and tolerability of glatiramer acetate (GA) 40mg as compared to the approved COPAXONEŽ 20mg in the treatment of relapsing-remitting multiple sclerosis (RRMS).
The 40mg dose did not demonstrate increased efficacy in reducing the relapse rate; however, the higher dose maintained the favourable safety and tolerability profile of COPAXONEŽ 20mg...................
For the full report please go to MSRC: MS Research News : Drugs : Disease Modifying Drugs : Disease Modifying Drugs Ongoing Research : COPAXONEŽ Ongoing Research (http://www.msrc.co.uk/index.cfm?fuseaction=show&pageid=1767)
The 40mg dose did not demonstrate increased efficacy in reducing the relapse rate; however, the higher dose maintained the favourable safety and tolerability profile of COPAXONEŽ 20mg...................
For the full report please go to MSRC: MS Research News : Drugs : Disease Modifying Drugs : Disease Modifying Drugs Ongoing Research : COPAXONEŽ Ongoing Research (http://www.msrc.co.uk/index.cfm?fuseaction=show&pageid=1767)